Back to discover

Protein / target

C-X-C motif chemokine 13

Encoded byCXCL13O43927Homo sapiensSwiss-Prot
UniProt: O43927Ensembl: ENSG00000156234HGNC: HGNC:10639NCBI Gene: 10563
Antibody-tractable
Druggability
GO CC high conf
2
Research papers

Protein at a glance

Biological role

CCR10 chemokine receptor binding

Strongest disease association

Arthritis, Rheumatoid

Via encoding gene CXCL13 · Genetic evidence · score 0.63

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils.

View complete UniProt function annotation

Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5

Subcellular location

Secreted
Domains and Gene Ontology detail (32)

Gene Ontology

  • Cextracellular region
  • Cextracellular space
  • FCCR10 chemokine receptor binding
  • Fchemokine activity
  • FCXCR chemokine receptor binding
  • FCXCR3 chemokine receptor binding
  • FCXCR5 chemokine receptor binding
  • Ffibroblast growth factor binding
  • Fheparin binding
  • Freceptor ligand activity
  • Pantimicrobial humoral immune response mediated by antimicrobial peptide
  • PB cell chemotaxis

109 aa · 13 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOGrowth-factor signallingGOImmune signallingGO
View supporting evidence

Cell migration

  • ·B cell chemotaxis
  • ·endothelial cell chemotaxis to fibroblast growth factor
  • ·lymphocyte chemotaxis across high endothelial venule
  • ·negative regulation of endothelial cell chemotaxis to fibroblast growth factor

Growth-factor signalling

  • ·fibroblast growth factor binding
  • ·endothelial cell chemotaxis to fibroblast growth factor
  • ·negative regulation of endothelial cell chemotaxis to fibroblast growth factor

Immune signalling

  • ·antimicrobial humoral immune response mediated by antimicrobial peptide
  • ·B cell chemotaxis
  • ·chronic inflammatory response
  • ·immune response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CXCL13

Gene-level evidence surfaced through the gene CXCL13that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Arthritis, Rheumatoid
0.70Moderately supported

Genetic evidence dominant · Open Targets 0.42

Myasthenia Gravis
0.51Moderately supported

Genetic evidence dominant · Open Targets 0.30

Neurodegenerative Diseases
0.26Preliminary

Pathway evidence dominant · Open Targets 0.39 · no direct causal or clinical evidence

Alcohol drinking
0.22Preliminary

Genetic evidence dominant · Open Targets 0.13

View evidence synthesis (4)
Arthritis, RheumatoidModerately supported
0.70
agreement 0.57–0.82
Genetic78%Literature17%RNA expression5%

Open Targets aggregate 0.42 · 3 independent evidence families

Myasthenia GravisModerately supported
0.51
agreement 0.37–0.65
Genetic85%Literature15%

Open Targets aggregate 0.30 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.26
agreement 0.08–0.44
Pathway99%Literature1%

Open Targets aggregate 0.39 · 2 independent evidence families · no direct causal or clinical evidence

Alcohol drinkingPreliminary
0.22
agreement 0.08–0.36
Genetic98%Literature2%

Open Targets aggregate 0.13 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Arthritis, Rheumatoid0.42
Neurodegenerative Diseases0.39
Myasthenia Gravis0.30
Alcohol drinking0.13

Tractability

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · Database Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.42 cites

Han PZ · JCI insight · 2024

Chemokine CXCL13-CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain and neurological diseases.14 cites

Zheng K · Cellular & molecular biology letters · 2024

Recent

A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.

Han PZ · JCI insight · 2024

Chemokine CXCL13-CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain and neurological diseases.

Zheng K · Cellular & molecular biology letters · 2024

Europe PMC papers linked directly to this protein.